CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...